AKT1 and Bloom syndrome: In vitro experiments further verified that CDN inhibits BLM-induced epithelial–mesenchymal transition (EMT) by suppressing the IGF1/PI3K/AKT axis—this inhibitory effect was reversed by exogenous IGF1 supplementation and enhanced by the PI3K inhibitor LY294002.